Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare Biotechnology

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger)

Bullboard Posts

Comment by jombyon Jun 17, 2020 11:42pm

134 Views

Post# 31163267

RE:RE:RE:Just Relax

actually shares were never at .15 cents in 2014.they were above .50 all year,but there was a massive dump due to abandonment clinical trial due to safety concerns jan 16th 2015, the shares did hit .08 cents.so I would say because it;s been six years ago.memory of time and events do fade a little.so I beleive it.5 million at .15 cents yea,very possible.

Bullboard Posts

NervGen Pharma: Proof that NVG-291 works?